The Florida Senate

COMMITTEE MEETING EXPANDED AGENDA

HEALTH POLICY Senator Diaz, Chair Senator Brodeur, Vice Chair

MEETING DATE: Wednesday, October 13, 2021

TIME: 9:00—11:30 a.m.

PLACE: Pat Thomas Committee Room, 412 Knott Building

MEMBERS: Senator Diaz, Chair; Senator Brodeur, Vice Chair; Senators Albritton, Baxley, Bean, Book, Cruz,

Garcia, Jones, and Powell

TAB	BILL NO. and INTRODUCER	BILL DESCRIPTION and SENATE COMMITTEE ACTIONS	COMMITTEE ACTION
1	Update on COVID-19 status and mitigation efforts by the Department of Health and the Agency for Health Care Administration		
	Other Related Meeting Documents		

Florida's COVID-19 Response Updates

Senate Health Policy Committee October 13, 2021



Melissa Murray Jordan, MS, MPH Director, Division of Community Health Promotion Florida Department of Health



The Florida Department of Health (FDOH), comprised of a state health office in Tallahassee and 67 county health departments, operates as an integrated public health system.



Florida's COVID-19 Response

Protect the Vulnerable Seniors First			
Education	Prevention	Treatment	
Educate and inform Floridians on the benefits of COVID-19 vaccines.	Ensure COVID-19 testing and vaccine resources are available and accessible statewide.	Ensure authorized and approved COVID-19 treatments are available and accessible statewide.	



COVID-19 Cases




_

COVID-19 Cases and Deaths by Race and Ethnicity March 1, 2020 - October 7, 2021

	Cases	Cases per 100,000	Deaths	Case Fatality Rate
Total	3,601,755	16,390	56,667	1.6%
Race				
Black	517,663	13,896	9,455	1.8%
White	2,083,226	12,272	41,001	2.0%
Other	539,641	42,339	4,640	0.9%
Unknown	461,225	N/A	1,571	N/A
Ethnicity				
Hispanic	1,090,853	18,584	12,206	1.1%
Non-Hispanic	1,920,759	11,926	40,853	2.1%
Unknown	590,143	N/A	3,608	N/A




7-Day Average Case Trends September 1, 2021 - September 30, 2021





6

Age-Adjusted COVID-19 Mortality Rate per 100,000 by State January 1, 2020 - October 2, 2021





COVID-19 Vaccinations



COVID-19 Vaccines

COVID-19 vaccines that have received emergency use authorization (EUA) and/or approval from the U.S. Food and Drug Administration (FDA):

- Pfizer-BioNTech COVID-19 Vaccine, December 11, 2020
 - EUA expanded to include ages 12-15 (May 10, 2021).
 - FDA approved for ages 16 and older under the name Comirnaty (August 23, 2021).
 - Two doses, 21 days apart.
- Moderna COVID-19 Vaccine, December 18, 2020
 - Ages 18 and older.
 - Two doses, 28 days apart.
- Janssen COVID-19 Vaccine (Johnson & Johnson), February 27, 2021
 - Ages 18 and older.
 - One dose.



Additional Dose and Booster Dose

Individuals should talk to their health care provider about whether getting a COVID-19 vaccine additional dose or booster dose is appropriate for them.

Additional Dose

- To mount a strong immune response among moderately and severely immunocompromised individuals.
- Pfizer-BioNTech and Moderna COVID-19 vaccines.

Booster Dose

- To increase the immune response of individuals who have completed the recommended number of initial doses for a COVID-19 vaccine.
- Pfizer-BioNTech COVID-19 vaccine.



COVID-19 Vaccine Additional Dose

On August 12, 2021, the EUAs for Pfizer-BioNTech and Moderna COVID-19 vaccines were amended to include an additional (third) dose for moderately and severely immunocompromised individuals.

Guidance

- Pfizer-BioNTech: Ages 12 and older.
- Moderna: Ages 18 and older.
- Administered at least 28 days following the two-dose regimen.




COVID-19 Vaccine Booster Dose

On September 22, 2021, the EUA was amended for Pfizer-BioNTech COVID-19 vaccine to allow for a single booster dose to be administered at least six months after completion of the primary two-dose series in individuals:

- Ages 65 and older.
- Ages 18-64 who have underlying medical conditions.
- Ages 18-64 at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting.
- Ages 18-64 who live in long-term care settings.



Cumulative Individuals Vaccinated by Week Against COVID-19 December 11, 2020 - October 7, 2021



Week start date





COVID-19 Vaccinations by Age Group December 11, 2020 - October 7, 2021

Age Group	2021 Population	Vaccinated	% of Population Vaccinated
12-19	1,972,084	1,079,179	55%
20-29	2,744,987	1,467,497	53%
30-39	2,784,698	1,750,543	63%
40-49	2,669,253	1,902,505	71%
50-59	2,925,172	2,250,328	77%
60-64	1,438,783	1,203,919	84%
65+	4,584,066	4,064,979	89%



COVID-19 Vaccinations by Race and Ethnicity December 11, 2020 - October 7, 2021

	2021 Population Ages 12+	Vaccinated	% of Eligible Population Vaccinated	
Race				
Black	3,092,685	1,217,993	39%	
White	14,994,181	8,352,789	56%	
Other	1,032,177	2,240,980	*	
Unknown	N/A	1,907,194	N/A	
Ethnicity				
Hispanic	4,935,168	3,084,297	62%	
Non-Hispanic	14,183,875	6,473,542	46%	
Unknown	N/A	4,161,117	N/A	

^{*}For individuals who identify as Other, the vaccinated population is larger than the 2021 population estimates.







COVID-19 Vaccination Rates per 100,000 Population December 11, 2020 - October 7, 2021

Counties with the Highest Rates

County	2021 Population Ages 12+	Percent of Population
Miami-Dade	2,523,479	92%
Broward	1,692,280	82%
Monroe	68,463	81%
Osceola	338,740	79%
Sarasota	401,856	76%





COVID-19 Vaccination Communication Strategies



COVID-19 Vaccination Communication Efforts




The FDOH is actively deploying statewide media campaigns to provide the public with information about COVID-19 vaccines and encourage vaccination statewide.

- Digital and Social Media Ads: Reached more than 19.5 million people and generated more than 107.8 million impressions.
- TV and Radio Ads: Generated more than 23.8 million impressions.



COVID-19 Vaccine Toolkit for Partners



Social Media Images

Digital Display Assets



DOWNLOAD HERE

Billboard Ads

DOWNLOAD HERE

Print Ads



- FDOH developed and disseminated a toolkit to partners including the Florida Department of Elder Affairs, Agency for Health Care Administration, Florida Department of Children and Families, and others.
- Features campaign assets that can be used for any promotional efforts related to the COVID-19 vaccines.
- The toolkit is available for partners to <u>download online</u>.

COVID-19 Monoclonal Antibody Therapy Treatment



Monoclonal Antibody Therapy Treatment

- Monoclonal antibody therapy treatment is for individuals who have contracted or been exposed to COVID-19:
 - Reduces the risk of death/hospitalization by 70 − 85%.
 - Reduces the risk of developing symptomatic disease by over 80%.
 - Can help eliminate outbreaks in long-term care facilities.
- Florida was among the first in the nation to significantly expand access to these treatments for both COVID-19 positive and exposed individuals.
- Providing these treatments outside of hospitals afforded the opportunity for hospitals to devote resources to more seriously ill patients and reduced COVID-19 admissions.

Monoclonal Antibody Therapy Treatment

Three COVID-19 monoclonal antibody therapy treatments have received EUA from the FDA:

REGEN-COV

- COVID-19 positive patients ages 12 and older.
- Amended to include post-exposure prophylaxis use (July 30, 2021).
- Outpatient treatment via IV infusion or subcutaneous injection (June 3, 2021).

Bamlanivimab and Etesevimab

- COVID-19 positive patients ages 12 and older.
- Amended to include post-exposure prophylaxis use (September 16, 2021).
- Outpatient treatment via IV infusion.

Sotrovimab

- COVID-19 positive patients ages 12 and older.
- Outpatient treatment via IV infusion.



Monoclonal Antibody Therapy Treatment

- 25 treatment sites opened between August 12, 2021 – September 9, 2021.
- Sites average nearly 3,000 combined doses daily.
- A total of 135,919 doses administered as of October 10, 2021.
- Strike Teams have provided 721 treatments in 50 longterm care facilities as of October 10, 2021.





Resources

- Weekly Florida Summary Statistics
 - https://floridahealthcovid19.gov/
- Daily Cases and Death
 - https://covid.cdc.gov/covid-data-tracker/#trends_dailycases
- 7-Day Average County Data
 - https://covid.cdc.gov/covid-data-tracker/#county-view
- Community Profile Report
 - https://healthdata.gov/Health/COVID-19-Community-Profile-Report/gqxmd9w9
- Hospitalization Admissions
 - https://covid.cdc.gov/covid-data-tracker/#new-hospital-admissions



Thank you!





COVID-19 RESPONSE UPDATE

Senate Health Policy Committee

Kimberly Smoak
Deputy Secretary of Health Quality Assurance

October 13, 2021

COVID-19 RESPONSE UPDATES

- Federal Regulatory Flexibilities
- Hospital Updates
- Long-Term Care Updates
- Infection Control & Prevention Efforts



FEDERAL REGULATORY WAIVERS

As with most emergencies, the Federal Centers for Medicare and Medicaid Services instituted a series of regulatory flexibilities in response to COVID-19.

Nursing Homes

- Waiver of 3-day prior hospitalization for Medicare reimbursement
- Flexibility in room utilization to accommodate surge

Hospitals

- Alternate Care Sites
- Acute care at home/hospitals without walls

All Providers

- Waiver of certain physical environment requirements
- Waiver of prescriptive requirements for alcohol-based hand-rub dispensers



HOSPITAL UPDATES

HOSPITAL CAPACITY

- As a result of Governor DeSantis' leadership in expanding access to Monoclonal Antibody Treatments, Florida Hospitals have experienced an over 73% decrease in hospitalizations, accounting for a more than 40-day consecutive decline.
- During the most recent surge in hospitalizations, hospitals continued to provide non-COVID related emergency and surgical care, including elective surgeries, which attributed to the overall Hospital capacity/census level.
- Access to Monoclonal Antibody Therapy and Vaccine ensures hospitals have the bed capacity for Floridians seeking other lifesaving services.
- As of October 9, only 6.78% of Inpatient Beds and 17.05% of ICU beds were in use for COVID-19, below the national average of 8.53% and 21.47% respectively.



LONG-TERM CARE UPDATES

ENGAGEMENT AND COLLABORATION

- The Agency remains committed to ensuring the safety of Florida's seniors residing in Long-Term Care facilities.
- From the onset of the pandemic, Governor DeSantis' Senior First strategy has prioritized seniors access to health care services, including COVID-19 vaccinations.
- This commitment also includes ensuring Monoclonal Antibody Therapy is available to Long-Term Care facilities.
- As a result of Governor DeSantis' leadership in expanding access to Monoclonal Antibody Treatments, Nursing Homes have experienced an over 124% decrease in staff cases and 71% decrease in resident cases.
- The Agency continues to conduct outreach to health care associations and providers on third doses and boosters.



LONG-TERM CARE UPDATES

INFECTION CONTROL & PREVENTION

- The Agency continues to work in partnership with the Department of Health's Health Care Associated Infection Team (HAI Team) to ensure the safety and sanitation of Long-Term Care facilities.
- This includes conducting joint visits to facilities and providing educational resources on appropriate infection control and prevention standards.
- Infection control and prevention is also reviewed during each facility's recertification survey.



LONG-TERM CARE UPDATES

INFECTION CONTROL & PREVENTION

- The Agency also completes Focused Infection Control Surveys as required by the Federal Centers for Medicare and Medicaid Services (CMS).
- Infection Control Surveys:
 - All Nursing Home related case information is now reported directly to CMS, through the National Healthcare Safety Network.
 - This reporting initially began in June 2020 and was expanded in June 2021.
 - Nursing Homes are identified for surveys based on this criteria:
 - 3 or more Resident Positive Cases since last reporting
 - 1 or More Resident Cases from COVID-Free



QUESTIONS?

